Daniela Yuschenkoff, Gretchen A Cole, Jennifer D'Agostino, Brad Lock, Sherry Cox, Kurt K Sladky
{"title":"巨龟(chelonoidis vandenburghi, chelonoidis vicina)体内曲马多和邻去甲基曲马多的药代动力学。","authors":"Daniela Yuschenkoff, Gretchen A Cole, Jennifer D'Agostino, Brad Lock, Sherry Cox, Kurt K Sladky","doi":"10.1638/2023-0062","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this study was to determine the pharmacokinetics of two orally administered doses of tramadol (1 mg/kg and 5 mg/kg) and its metabolite, O-desmethyltramadol (M1) in giant tortoises (<i>Chelonoidis vandenburghi</i>, <i>Chelonoidis vicina</i>). Eleven giant tortoises (<i>C. vandenburghi</i>, <i>C. vicina</i>) received two randomly assigned, oral doses of tramadol (either 1 mg/kg or 5 mg/kg), with a washout period of 3 wk between each dose. The half-life (t½) of orally administered tramadol at 1 mg/kg and 5 mg/kg was 11.9 ± 4.6 h and 13.2 ± 6.1 h, respectively. After oral administration of tramadol at 1 mg/kg and 5 mg/kg, the maximum concentration (C<sub>max</sub>) was 125 ± 69 ng/ml and 518 ± 411 ng/ml, respectively. There were not enough data points to determine pharmacokinetic (PK) parameters for the M1 metabolite from either dose. Tramadol administered orally to giant tortoises at both doses provided measurable plasma concentrations of tramadol for approximately 48 h with occasional transient sedation. Oral tramadol at 5 mg/kg, on average, achieves concentrations of >100 ng/ml, the reported human therapeutic threshold, for 24 h. Based on the low levels of M1 seen in this study, M1 may not be a major metabolite in this taxon.</p>","PeriodicalId":17667,"journal":{"name":"Journal of Zoo and Wildlife Medicine","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN GIANT TORTOISES (<i>CHELONOIDIS VANDENBURGHI</i>, <i>CHELONOIDIS VICINA</i>).\",\"authors\":\"Daniela Yuschenkoff, Gretchen A Cole, Jennifer D'Agostino, Brad Lock, Sherry Cox, Kurt K Sladky\",\"doi\":\"10.1638/2023-0062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The objective of this study was to determine the pharmacokinetics of two orally administered doses of tramadol (1 mg/kg and 5 mg/kg) and its metabolite, O-desmethyltramadol (M1) in giant tortoises (<i>Chelonoidis vandenburghi</i>, <i>Chelonoidis vicina</i>). Eleven giant tortoises (<i>C. vandenburghi</i>, <i>C. vicina</i>) received two randomly assigned, oral doses of tramadol (either 1 mg/kg or 5 mg/kg), with a washout period of 3 wk between each dose. The half-life (t½) of orally administered tramadol at 1 mg/kg and 5 mg/kg was 11.9 ± 4.6 h and 13.2 ± 6.1 h, respectively. After oral administration of tramadol at 1 mg/kg and 5 mg/kg, the maximum concentration (C<sub>max</sub>) was 125 ± 69 ng/ml and 518 ± 411 ng/ml, respectively. There were not enough data points to determine pharmacokinetic (PK) parameters for the M1 metabolite from either dose. Tramadol administered orally to giant tortoises at both doses provided measurable plasma concentrations of tramadol for approximately 48 h with occasional transient sedation. Oral tramadol at 5 mg/kg, on average, achieves concentrations of >100 ng/ml, the reported human therapeutic threshold, for 24 h. Based on the low levels of M1 seen in this study, M1 may not be a major metabolite in this taxon.</p>\",\"PeriodicalId\":17667,\"journal\":{\"name\":\"Journal of Zoo and Wildlife Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Zoo and Wildlife Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1638/2023-0062\",\"RegionNum\":4,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Zoo and Wildlife Medicine","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1638/2023-0062","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN GIANT TORTOISES (CHELONOIDIS VANDENBURGHI, CHELONOIDIS VICINA).
The objective of this study was to determine the pharmacokinetics of two orally administered doses of tramadol (1 mg/kg and 5 mg/kg) and its metabolite, O-desmethyltramadol (M1) in giant tortoises (Chelonoidis vandenburghi, Chelonoidis vicina). Eleven giant tortoises (C. vandenburghi, C. vicina) received two randomly assigned, oral doses of tramadol (either 1 mg/kg or 5 mg/kg), with a washout period of 3 wk between each dose. The half-life (t½) of orally administered tramadol at 1 mg/kg and 5 mg/kg was 11.9 ± 4.6 h and 13.2 ± 6.1 h, respectively. After oral administration of tramadol at 1 mg/kg and 5 mg/kg, the maximum concentration (Cmax) was 125 ± 69 ng/ml and 518 ± 411 ng/ml, respectively. There were not enough data points to determine pharmacokinetic (PK) parameters for the M1 metabolite from either dose. Tramadol administered orally to giant tortoises at both doses provided measurable plasma concentrations of tramadol for approximately 48 h with occasional transient sedation. Oral tramadol at 5 mg/kg, on average, achieves concentrations of >100 ng/ml, the reported human therapeutic threshold, for 24 h. Based on the low levels of M1 seen in this study, M1 may not be a major metabolite in this taxon.
期刊介绍:
The Journal of Zoo and Wildlife Medicine (JZWM) is considered one of the major sources of information on the biology and veterinary aspects in the field. It stems from the founding premise of AAZV to share zoo animal medicine experiences. The Journal evolved from the long history of members producing case reports and the increased publication of free-ranging wildlife papers.
The Journal accepts manuscripts of original research findings, case reports in the field of veterinary medicine dealing with captive and free-ranging wild animals, brief communications regarding clinical or research observations that may warrant publication. It also publishes and encourages submission of relevant editorials, reviews, special reports, clinical challenges, abstracts of selected articles and book reviews. The Journal is published quarterly, is peer reviewed, is indexed by the major abstracting services, and is international in scope and distribution.
Areas of interest include clinical medicine, surgery, anatomy, radiology, physiology, reproduction, nutrition, parasitology, microbiology, immunology, pathology (including infectious diseases and clinical pathology), toxicology, pharmacology, and epidemiology.